Curcumin Supplement Tested in Locally Advanced Cervical Cancer Patients
Tests curcumin tablets, with or without piperine, in adults with locally advanced cervical cancer.
Plain-language title generated from the registry record
Registry title: Curcumin Supplementation in Cervical Cancer
Key facts
- Where
- Mexico City, MexicoSee the site
Where in Mexico
- Instituto Nacional de CancerologiaMexico City, MexicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Institute of Cancerología
- Trial code
- NCT06080841
- Record updated
- 25 May 2025
- Original description
Brief Summary.Read full original descriptionShow less
Evaluation of Curcumin Supplementation on p53 Levels and Apoptosis in Tumor Cells From Patients With Locally Advanced Cervical Cancer
Brief Summary.
The goal of this pilot study is to learn about the effect of curcumin supplementation in locally advanced cervical cancer patients. The main questions it aims to answer are:
* Does curcumin supplementation increase the levels of p53 and apoptosis in tumor cells from cervical cancer patients? * At which dose of curcumin supplementation is the broader effect observed for p53 expression and apoptosis in tumor cells from cervical cancer patients? * Are all doses safe for supplementation?
Participants will be asked to take curcumin tablets throughout their cancer treatment. Researchers will compare 6 different groups, each group will receive a different dose of curcumin with or without piperin, to see the dose with the broader effect and safety of curcumin supplementation:
1. 1 g of curcumin 2. 1 g of curcumin + piperine 3. 3 g of curcumin 4. 3 g of curcumin + piperine 5. 6 g of curcumin 6. 6 g of curcumin + piperine
Inclusion: Understanding the nature of the study and giving a written consent report; Women > 18 years old; ECOG performance status: 0-2; Be willing and able to comply with scheduled visits, treatment plans, and laboratory tests; Patients with a histological cervical cancer diagnosis: squamous cell, adenosquamous, adenocarcinoma, and glassy cell carcinoma; Classified with clinical stage IB3-IVA (FIGO 2018); Candidates to receive concomitant QT-RT followed by BT; With disease measurable by any imaging method (CT/MRI/PET-CT) according to RECIST v 1.1 criteria; Patients without prior treatment based on QT-RT; Hemoglobin ≥ 10 g/dL; Leukocytes ≥ 4000/mm3; Platelets ≥ 100,000/mm3; Adequate liver function.
Exclusion: Patients receiving concomitant treatment with an experimental drug; Patients with previous or concomitant malignancy except non-melanoma skin carcinoma; Patients with uncontrolled intercurrent diseases, including active infections that contraindicate CT; Patients with vesicovaginal or vesicorectal fistula are diagnosed; Patients undergoing nutritional treatment or ingesting any dietary supplement, including those containing turmeric or turmeric derivatives, ginger, or rhizome of the turmeric family.